科倫藥業(002422.SZ):擬推出員工持股計劃
格隆匯11月22日丨科倫藥業(002422.SZ)公佈,公司為進一步完善和提升員工激勵機制,改善公司治理水平,結合公司高質量發展的戰略目標,提高員工的凝聚力和公司競爭力,實現公司、股東和員工利益的一致性,促進公司長期穩健發展。根據規定,結合公司實際情況,擬推出員工持股計劃。
在符合相關法律法規規定的前提下,此次員工持股計劃所持有的公司股票總數預計不超過104萬股,佔公司股本總額的比例不超過0.0730%;單一持有人持有的員工持股計劃份額所對應的公司股票數量不超過公司股本總額的 1%。具體持股規模以後續審議披露的持股計劃草案和員工實際繳納出資為準。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.